IP Library Granted Patent US 7,132,569
Granted Patent B2
US 7,132,569 · App. 11/254,749 · Granted Nov 7, 2006

Preparation of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,132,569
App. No.
11/254,749
Granted
Nov 7, 2006
Kind
B2
Abstract

From compounds of formula II wherein R 1 and R 2 are independently of one another H, C 1 –C 6 alkyl, C 1 –C 6 halogenalkyl, C 1 –C 6 alkoxy, C 1 –C 6 alkoxy-C 1 –C 6 alkyl, or C 1 –C 6 alkoxy-C 1 –C 6 alkyloxy, R 3 is C 1 –C 6 alkyl, R 4 is C 1 –C 6 alkyl, and R 5 is C 1 –C 6 alkyl, C 1 –C 6 hydroxyalkyl, C 1 –C 6 alkoxy-C 1 –C 6 -alkyl, C 1 –C 6 alkanoyloxy-C 1 –C 6 alkyl, C 1 –C 6 aminoalkyl, C 1 –C 6 alkylamino-C 1 –C 6 -alkyl, C 1 –C 6 -dialkylamino-C 1 –C 6 -alkyl, C 1 –C 6 -alkanoylamido-C 1 –C 6 -alkyl, HO(O)C—C 1 –C 6 -alkyl, C 1 –C 6 alkyl-O—(O)C—C 1 –C 6 alkyl, H 2 N—C(O)—C 1 –C 6 alkyl, C 1 –C 6 alkyl-HN—C(O)—C 1 –C 6 alkyl or (C 1 –C 6 alkyl) 2 N—C(O)—C 1 –C 6 -alkyl, R 6 is C 1 –C 6 alkyl, R 7 is C 1 –C 6 alkyl or C 1 –C 6 alkoxy, or R 6 and R 7 together are tetramethylene, pentamethylene, 3-oxa-1,5-pentylene or —CH 2 CH 2 O— substituted, if necessary, with C 1 –C 4 -Alkyl, phenyl or benzyl, it is possible—through halolactonization, azidation of the halogen group, ring opening with an amine R 5 —NH 2 , and reduction of the azide group to form the amino group—to prepare compounds of formula I wherein R 5 is C 1 –C 6 alkyl, C 1 –C 6 hydroxyalkyl, C 1 –C 6 alkoxy-C 1 –C 6 alkyl, C 1 –C 6 alkanoyloxy-C 1 –C 6 alkyl, C 1 –C 6 aminoalkyl, C 1 –C 6 alkylamino-C 1 –C 6 alkyl, C 1 –C 6 dialkylamino-C 1 –C 6 -alkyl, C 1 –C 6 alkanoylamido-C 1 –C 6 alkyl, HO(O)C—C 1 –C 6 alkyl, C 1 –C 6 alkyl-O—(O)C—C 1 –C 6 alkyl, H 2 N—C(O)—C 1 –C 6 alkyl, C 1 –C 6 alkyl-HN—C(O)—C 1 –C 6 alkyl or (C 1 –C 6 alkyl) 2 —N—C(O)—C 1 –C 6 alkyl. If 2(S),7(R)-diastereomer of formula II is used, the 2(S),4(S),5(S),7(S)-diastereomer of formula Ia is obtained in a high degree of purity.

Claims (17)

1. A compound of formula II

wherein R 1 and R 2 are independently of one another H, C 1 –C 6 alkyl, C 1 –C 6 halogenalkyl, C 1 –C 6 alkyloxy, C 1 –C 6 alkoxy-C 1 –C 6 alkyl or C 1 –C 6 alkoxy-C 1 –C 6 alkyloxy, R 3 is C 1 –C 6 alkyl, R 4 is C 1 –C 6 alkyl, R 6 is C 1 –C 6 alkyl, and R 7 is C 1 –C 6 alkyl or C 1 –C 6 alkoxy, or R 6 and R 7 together are tetramethylene, pentamethylene, 3-oxa-1,5-pentylene or —CH 2 CH 2 O—C(O)— optionally substituted with C 1 –C 4 alkyl, phenyl or benzyl.

2. A compound according to claim 1 , wherein R 1 is 1-methoxyprop-3-yloxy, R 2 is methoxy, R 3 and R 4 are isopropyl and R 6 is methyl or ethyl, R 7 is methyl, ethyl or methoxy, or R 6 and R 7 together are tetramethylene, pentamethylene or —CH(CH 2 C 6 H 5 )CH 2 —O—C(O)—.

3. A compound according to claim 1 , that corresponds to formula IIa

wherein R 1 and R 2 are independently of one another H, C 1 –C 6 alkyl, C 1 –C 6 halogenalkyl, C 1 –C 6 alkoxy, C 1 –C 6 alkoxy-C 1 –C 6 alkyl, or C 1 –C 6 alkoxy-C 1 –C 6 alkyloxy, R 3 is C 1 –C 6 alkyl, R 4 is C 1 –C 6 alkyl, R 6 is C 1 –C 6 alkyl and R 7 is C 1 –C 6 alkyl or C 1 –C 6 alkoxy, or R 6 and R 7 together are tetramethylene, pentamethylene, 3-oxa-1,5-pentylene or —CH 2 CH 2 O—C(O)— optionally substituted with C 1 –C 4 alkyl, phenyl or benzyl.

4. A compound of formula III

wherein R 1 and R 2 are independently of one another H, C 1 –C 6 alkyl, C 1 –C 6 halogenalkyl, C 1 –C 6 alkoxy, C 1 –C 6 alkoxy-C 1 –C 6 alkyl, or C 1 –C 6 alkoxy-C 1 –C 6 alkyloxy, R 3 is C 1 –C 6 alkyl R 4 is C 1 –C 6 alkyl, and X is Cl, Br, I or N 3 .

5. A compound according to claim 4 wherein R 1 is 1-methoxyprop-3-yloxy, R 2 is methoxy, R 3 and R 4 are isopropyl and X is Cl, Br, I or N 3 .

6. A compound according to claim 5 , that corresponds to formula IIIa

wherein R 1 and R 2 are independently of one another H, C 1 –C 6 alkyl, C 1 –C 6 halogenalkyl, C 1 –C 6 alkoxy, C 1 –C 6 alkoxy-C 1 –C 6 alkyl, or C 1 –C 6 alkoxy-C 1 –C 6 alkyloxy, R 3 is C 1 –C 6 alkyl, R 4 is C 1 –C 6 alkyl, and X is Cl, Br, I or N 3 .

7. A compound of formula VII in the form of its racemate or enantiomer

wherein R 4 is C 1 –C 6 alkyl, R 6 is C 1 –C 6 alkyl, and R 7 is C 1 –C 6 alkyl or C 1 –C 6 alkoxy, or R 6 and R 7 together are tetramethylene, pentamethylene, 3-oxa-1,5-pentylene or —CH 2 CH 2 O—C(O)— optionally substituted with C 1 –C 4 alkyl, phenyl or benzyl, and Z is Cl, Br or I.

8. A compound according to claim 7 , wherein R 4 is 1-methyl ethyl, Z is Cl, and R 6 is methyl or ethyl, R 7 is methyl, ethyl or methoxy, or R 6 and R 7 together are tetramethylene, pentamethylene or —CH(CH 2 C 6 H 5 )CH 2 —O—CO—.

9. A compound according to claim 7 , that corresponds to formula VIIa

wherein R 4 is C 1 –C 6 alkyl, R 6 is C 1 –C 6 alkyl, and R 7 is C 1 –C 6 alkoxy, or R 6 and R 7 together are tetramethylene, pentamethylene, 3-oxa-1,5-pentylene or —CH 2 CH 2 O—C(O)— optionally substituted with C 1 –C 4 alkyl, phenyl or benzyl, and Z is Cl, Br or I.

10. A compound according to claim 2 , that corresponds to formula IIa

wherein R 1 and R 2 are independently of one another H, C 1 –C 6 alkyl, C 1 –C 6 halogenalkyl, C 1 –C 6 alkoxy, C 1 –C 6 alkoxy-C 1 –C 6 alkyl, or C 1 –C 6 alkoxy-C 1 –C 6 alkyloxy, R 3 is C 1 –C 6 alkyl, R 4 is C 1 –C 6 alkyl, R 6 is C 1 –C 6 alkyl, and R 7 is C 1 –C 6 alkyl or C 1 –C 6 alkoxy, or R 6 and R 7 together are tetramethylene, pentamethylene, 3-oxa-1,5-pentylene or —CH 2 CH 2 O—C(O)— optionally substituted with C 1 –C 4 alkyl, phenyl or benzyl.

Assignments (4)
CHANGE OF ADDRESS Recorded Mar 21, 2017
From: NODEN PHARMA DAC
To: NODEN PHARMA DAC
Reel/Frame 042084/0980 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED ON REEL 039481 FRAME 0233. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 29, 2016
From: NOVARTIS AG; NOVARTIS PHARMA AG; SPEEDEL HOLDING AG
To: NODEN PHARMA DAC
Reel/Frame 040003/0579 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2016
From: NOVARTIS AG; NOVARTIS PHARMA AG; SPEEDEL HOLDING AG
To: NODEN PHARMA DAC
Reel/Frame 039481/0233 →
CHANGE OF ASSIGNEE ADDRESS Recorded Mar 6, 2006
From: SPEEDEL PHARMA AG
To: SPEEDEL PHARMA AG
Reel/Frame 017640/0422 →